中枢神经系统分布动力学 选择的基因素脱乙酶抑制剂的分布动力学
Wenqiu Zhang1, Ju-Hee Oh1, Wenjuan Zhang1
1Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, Minnesota.
The Journal of pharmacology and experimental therapeutics
|February 1, 2025
概括
像伏利诺斯塔特和奎西诺斯塔特这样的基因组脱乙酶抑制剂 (HDACIs) 由于快速降解和中枢神经系统暴露不足,显示出有限的脑瘤疗效. 了解它们的药理动力学对于优化脑癌治疗策略至关重要.
科学领域:
- 神经瘤学神经瘤学
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 基斯脱乙酶抑制剂 (HDACIs) 正在研究中枢神经系统 (CNS) 瘤,原因是基斯脱乙酶活性失调.
- 许多HDACIs在体外表现有前途,但在体内有效性适度,可能是由于中枢神经系统药物暴露不足.
研究的目的:
- 在小鼠模型中研究vorinostat和quisinostat的系统性药理动力学和中枢神经系统分布.
- 了解限制中枢神经系统对这些HDACI暴露的因素.
主要方法:
- 在小鼠的血和中枢神经系统中对伏利诺斯塔特和奎西诺斯塔特的药理动力学分析.
- 利用转基因载体缺乏的小鼠模型来评估血脑屏障载体的参与.
- 将中枢神经系统的分布动力学与panobinostat进行比较.
主要成果:
- 伏利诺斯塔特和奎西诺斯塔特都在小鼠血中经历了体外降解,并且体内半衰期很短.
- 中枢神经系统输送利诺斯塔特并没有受到P-gp或BCRP的限制.
- 不结合西诺斯塔的中枢神经系统暴露受到P-gp活性的限制.
结论:
- 伏利诺斯塔特和奎西诺斯塔特在血和中枢神经系统组织中容易降解.
- 通过尽量减少采样后降解来确定精确的中枢神经系统分布动力参数.
- 了解中枢神经系统暴露对于预测治疗窗口和指导中枢神经系统瘤中HDACI的剂量策略至关重要.
相关概念视频
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
902
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
902
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
75
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
75
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.0K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.0K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K
Depolarizing Blockers: Pharmocokinetics
305
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
305
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147


